{"name":"Charles River Laboratories","slug":"charles-river","ticker":"CRL","exchange":"NYSE","domain":"criver.com","description":"Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.","hq":"Wilmington, MA, USA","founded":1962,"employees":"18300","ceo":"James C. Foster","sector":"Preclinical CRO / Research Services","stockPrice":159.24,"stockChange":-3.61,"stockChangePercent":-2.22,"marketCap":"$7.7B","metrics":{"revenue":4027044096,"revenueGrowth":1.2,"grossMargin":34.5,"rdSpend":0,"netIncome":-144338000,"cash":191830000,"dividendYield":0,"peRatio":12.9,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"Lipitor patent cliff ($1.4B at risk)","drug":"Lipitor","type":"patent_expiry","sentiment":"negative"},{"date":"2020-06-01","label":"Viagra patent cliff ($null at risk)","drug":"Viagra","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Charles River Laboratories Reports Fourth Quarter and Full Year 2023 Results","summary":"Charles River Laboratories reported its fourth quarter and full year 2023 results, with revenue increasing 10% year-over-year.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Charles River Laboratories Acquires Cognita Labs","summary":"Charles River Laboratories acquired Cognita Labs, a provider of contract research services, to expand its capabilities in the preclinical CRO market.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves Charles River Laboratories' New Facility in China","summary":"The FDA approved Charles River Laboratories' new facility in China, which will support the company's growing presence in the Asian market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxObVVYMzNnRFBOaHNuc05zODRwQk5WZGxmOUtYTloyQVFXVnoyc21uSkoxTllzQnhyMFZzdXpxbFVoblg0YVY5VW1LYWVNblA0N3pZMzNLUGdXemJrSG1tQkp3SVZlQmtLTWVOdV9CcUpaRUdIVVhValVkVC1yeTVITjhOM0NhLTlScEJtdmFYTHE3dGhmcE4xajhSVDJXaGEwZlZxTXhaY2w1OTNYbHl0RUFUQmV1Z0VzaWZXMWRTRWZGSllN?oc=5","date":"2026-03-31","type":"pipeline","source":"AD HOC NEWS","summary":"Charles River Laboratories Stock: A Key Player in Drug Discovery Services for North American Investo - AD HOC NEWS","headline":"Charles River Laboratories Stock: A Key Player in Drug Discovery Services for North American Investo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNM1ppMlJ5Wml5XzJ1akVFMjQ3eFJFSFR3bkhrQTFCRDdweC1ReTBvT0hkMENyVFRreXk0cnpuLUNYcFBSeUJNYmswS0t4RWZwNVFWNVhYcm5CQ3lzZlo0amVISXNiZXJVTTBqYmowMDZnSDZybjdtWmR3Mm52V2hMdmJWb3ZaYkVoMnVsSE9idjhaQ003Z3R6cVlOcEppdDVfVDBxOWlSNE1hakpSTG1oT0tySHQycF9id0xkdVZn?oc=5","date":"2026-02-27","type":"pipeline","source":"European Pharmaceutical Review","summary":"Charles River Laboratories parts ways with its CDMO business | News - European Pharmaceutical Review","headline":"Charles River Laboratories parts ways with its CDMO business | News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPZ2RPUzNxRmhzM1ViNDMwaF9CenNrZ2RTTHVlbV95c0wwRV83dFJOVGVZY3VPeFBfSmJpS2JkRjlIcFI4NlJhWDVmYy1PWEVwQll3cExKYkdwOGRWaUFyS0pwaVVKSVNOTVd0OVozdkhabTlSSi1BNzhwa0VVYU4xSFJOampaMFJfZjZuYzlhZk1oMXA2VEpySkJZcU1fWThVYnh4MlFKMDhRZ3JpMUhLZlFhcE1IcUR2cVdaWXVFTE1PX3RxTUN4ZE81SFhKbFZSN1lBR0NCUWtLcHc?oc=5","date":"2026-02-25","type":"earnings","source":"reuters.com","summary":"Charles River raises annual profit view as it sells underperforming assets - reuters.com","headline":"Charles River raises annual profit view as it sells underperforming assets","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQSTJGVjJjSjlWdFFYdzI1ZlZYRWZhTy01UlBPWWozbFlYWGJZalZNRFR4dURyTG1CLVU1U0ROb0dWcklWMEVkMFVTVGI5ZzdFYnpLNmt2eTJ4ZGpvMHFIZWFvRmk2c3B0MEJpa2kwdWJhRWxsQkxoWUtHM0pYNE1EM2R5QUpfN2NKQ2ZWaXE0Vmo4RTU2UmZMY2pxOVZQZWFfT0JoNjdxcktGZVVXY0o5Y1hLYXQzeHc?oc=5","date":"2026-02-24","type":"pipeline","source":"Finviz","summary":"Baird Maintains Outperform Rating on Charles River Laboratories International, Inc. (CRL) - Finviz","headline":"Baird Maintains Outperform Rating on Charles River Laboratories International, Inc. (CRL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPandVNnFyUm9SSGRNLWd1aHdrZThMZllSMTB5aV8zQnJldlNuR1JpMmxMUEJOcjFRRFg2RHpZVXhaOU92NTJBdVlBY1Z3ZE1yMFd1dTJDREJUaGVzUHhGVkoyV1V2WXRuWHlQQXVob2N6T19Id0lXT2xvTkhkZUdPeFc3RV90cmZJVFN2SFQ3M0lRR0lhN29sZEwzdGk4WFRya0JDSllUSXBKZWpCN0stV1g5RjE2UVhhRUlzenhtajQ1NG8?oc=5","date":"2026-02-21","type":"pipeline","source":"AD HOC NEWS","summary":"Charles River Laboratories: Why This Quiet Giant Suddenly Matters to You - AD HOC NEWS","headline":"Charles River Laboratories: Why This Quiet Giant Suddenly Matters to You","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-18","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNSmV4emlubUhKSEJCaGJlM3ZXcndaWmwxWkhQQndKLWROWER2dGU2QU01aUpCWm1FeHQ5SVczZHlmelJ6RFh0NVBqZkFrYS16NnNQTDFZZV9Yc0ZwV1RxODltRllOSTlUYndRTS1JLTQ0Q3liQUJvb0djNDFaMDNnREthU3hEd0pIRHlNWERMTTNYUjB4MUZmbmtlcGFwSXEzQWljLVRrb1BKR0dIUXNnNG9wclNQVXluQUxDbWw4SQ?oc=5","date":"2026-01-28","type":"pipeline","source":"Fierce Biotech","summary":"Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says - Fierce Biotech","headline":"Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQVWwzTFhFQktXSDhPN09KWGZRY2NoRkJFS1ZINWxKVzRGdE5xenE1cW5mWk1qTHl4MzVzbnZ4RlZHN3hKQ2Rpb01JX2lyWWZjM243X2NTTUlFZWZveTNCbEpwT3N2NXVMZUt6bEdzMk5CY3kyQll1ZjR1bVZPZGRhYVJ2bzJYLU9idE13czY5SE1CTE1RbjVEeXhjakRwLXl6ejVUZ3RzMnE2WDVoSmZUU2lEckpGcWc2anh4em1iZjd0SktXVGhpYnlScV8?oc=5","date":"2026-01-13","type":"deal","source":"reuters.com","summary":"Charles River to buy Cambodia-based monkey supplier for $510 million - reuters.com","headline":"Charles River to buy Cambodia-based monkey supplier for $510 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNY2NJc2xUQ19tckFBdHRmMU5tZ2JFek5yQjlOek1wam9QS3oxRHdYU3k2bGV3UVVCX24zMUQ0TXBhWkdGM2l5NFRaeFg5ampvTVBiV1otbi16VmJQcUEwMTExb2tCNTFmUzZvdnpqYmtDSkZNWXNGQjM2V2YzVXMzZEg2NUtCTFlzR3BIUHpUVVRkaWMzVk85YnUtMXgwMzMwUmdjSXloMEtmdVZfeE94eFlfbVdWQ2NaLXBmUFBR?oc=5","date":"2026-01-13","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Charles River Laboratories Acquires PathoQuest and K.F. (Cambodia) - Genetic Engineering and Biotechnology News","headline":"Charles River Laboratories Acquires PathoQuest and K.F. (Cambodia)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQajVucGNlTlBtNGstMTJKczRReGNBcFpJclpyZGNwNENiLWJPeGtLa3NkOGp0S3lhelEzZGxnc3p5dUVkMTN2dDZZRE1MMUE1MXcwOGhpckNkRzJVWGxidzdWdS1PTVh5WU9LZWxORjljT3pFRnhGUk9FRzllanVoTTlxRThRbnF6R3FLTE9nQW5nSEc3aFpsVm01MGh2aFNmT2UyRUtfQWgyNEE5am41cHBZbjVidkd5YjhyekNKSE1tY29qWC1mdHdR?oc=5","date":"2025-11-16","type":"earnings","source":"Finviz","summary":"Drug Development Inputs & Services Stocks Q3 Teardown: Charles River Laboratories (NYSE:CRL) Vs The Rest - Finviz","headline":"Drug Development Inputs & Services Stocks Q3 Teardown: Charles River Laboratories (NYSE:CRL) Vs The Rest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPbDJibHBPTDlYdTlGOHhkY0FoQXhNVWlJdkoyYTBTU0d2Z1ZqZDgwYWloNWtKUEF2ZnFPMjVFSWEwcGgycHR5d202ZGk3ZFlWOVN0VzNBX1ZxUWV4OFB6UllIM0w2T2k5cWpOMWNjTm5WMm0wcmRMZVIzdmdNVWNHUHpISWpoOFlUTmxXZ1ZCT0puV3hseXlGT3BkaWljc2FQeUhWRU1OdS1NdFhhTzRybTVoTnY3c2pRTXFfOGJNX1NBSGpqVUo3Slp1WU1KVDdpTXQzX2xpR0lvcGRhQlBqNHROdUFhSXUyc0E1Q29xN2UtWThoSTdRQzRR?oc=5","date":"2025-10-08","type":"deal","source":"Business Wire","summary":"Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing - Business Wire","headline":"Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFAtVTE4bmFmbWtESVV2ZUtvZE9VdWFKZ3dQZVZKTUNvRlYzUUh5NUoxZVZycGJaZmJHU2NTeU02R1k4YzdiVjhYSzR4eGltMmNvVFJpRmhpX0hMUExGVjRyZWpyNmExSGh5bTNEenNZaEVnNWZJN2NoNUpB?oc=5","date":"2025-08-06","type":"pipeline","source":"The Business Journals","summary":"Charles River Labs cleared in DOJ monkey investigation, provides strategic review update - The Business Journals","headline":"Charles River Labs cleared in DOJ monkey investigation, provides strategic review update","sentiment":"neutral"}],"patents":[{"drugName":"Viagra","drugSlug":"sildenafil","patentNumber":"","type":"Patent Cliff","expiryDate":"2020-06-01","territory":"US"},{"drugName":"Lipitor","drugSlug":"atorvastatin","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["LabCorp","IQVIA","Parexel"],"therapeuticFocus":["Oncology","Infectious Diseases","Cardiovascular Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":1857601000,"revenuePeriod":"2017-12-30","revenueHistory":[{"value":1857601000,"period":"2017-12-30"},{"value":478477000,"period":"2017-12-30"},{"value":464232000,"period":"2017-09-30"},{"value":469129000,"period":"2017-07-01"},{"value":445763000,"period":"2017-04-01"}],"grossProfit":1323275000,"grossProfitHistory":[{"period":"2025-12-31","value":1323275000},{"period":"2024-12-31","value":1331821000},{"period":"2023-12-31","value":1502556000},{"period":"2022-12-31","value":1462651000}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":743073000,"operatingIncome":401136000,"operatingIncomeHistory":[{"period":"2025-12-31","value":401136000},{"period":"2024-12-31","value":442347000},{"period":"2023-12-31","value":617261000},{"period":"2022-12-31","value":650975000}],"netIncome":-144338000,"netIncomeHistory":[{"period":"2025-12-31","value":-144338000},{"period":"2024-12-31","value":10297000},{"period":"2023-12-31","value":474624000},{"period":"2022-12-31","value":486226000}],"eps":-2.91,"epsHistory":[{"period":"2025-12-31","value":-2.91},{"period":"2024-12-31","value":0.2},{"period":"2023-12-31","value":9.22},{"period":"2022-12-31","value":9.48}],"cash":213770000,"cashHistory":[{"period":"2025-12-31","value":213770000},{"period":"2024-12-31","value":194606000},{"period":"2023-12-31","value":276771000},{"period":"2022-12-31","value":233912000}],"totalAssets":7135422000,"totalLiabilities":3924228000,"totalDebt":2570408000,"equity":3164630000,"operatingCashflow":737646000,"operatingCashflowHistory":[{"period":"2025-12-31","value":737646000},{"period":"2024-12-31","value":734577000},{"period":"2023-12-31","value":683898000},{"period":"2022-12-31","value":619640000}],"capex":-219152000,"capexHistory":[{"period":"2025-12-31","value":-219152000},{"period":"2024-12-31","value":-232967000},{"period":"2023-12-31","value":-318528000},{"period":"2022-12-31","value":-324733000}],"freeCashflow":518494000,"dividendsPaid":null,"buybacks":-360673000,"employees":18300,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":196136000,"ebit":-270324000,"ebitda":-192047000,"period":"2025-12-31","revenue":994227000,"epsBasic":-5.62,"netIncome":-276555000,"rdExpense":null,"epsDiluted":-5.62,"grossProfit":309684000,"operatingIncome":92534000},{"sga":177589000,"ebit":112603000,"ebitda":197767000,"period":"2025-09-30","revenue":1004852000,"epsBasic":1.11,"netIncome":54422000,"rdExpense":null,"epsDiluted":1.1,"grossProfit":338792000,"operatingIncome":133799000},{"sga":191549000,"ebit":101385000,"ebitda":220892000,"period":"2025-06-30","revenue":1032135000,"epsBasic":1.06,"netIncome":52326000,"rdExpense":null,"epsDiluted":1.06,"grossProfit":357067000,"operatingIncome":100134000},{"sga":177799000,"ebit":63862000,"ebitda":184226000,"period":"2025-03-31","revenue":984168000,"epsBasic":0.5,"netIncome":25469000,"rdExpense":null,"epsDiluted":0.5,"grossProfit":317732000,"operatingIncome":74669000},{"sga":195708000,"ebit":-188557000,"ebitda":-86453000,"period":"2024-12-31","revenue":1002549000,"epsBasic":-4.22,"netIncome":-215699000,"rdExpense":null,"epsDiluted":-4.22,"grossProfit":284244000,"operatingIncome":47313000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":159.24,"previousClose":162.85,"fiftyTwoWeekHigh":228.88,"fiftyTwoWeekLow":132.58,"fiftyTwoWeekRange":"132.58 - 228.88","fiftyDayAverage":170.04,"twoHundredDayAverage":176.32,"beta":1.45,"enterpriseValue":10764535808,"forwardPE":12.9,"priceToBook":2.48,"priceToSales":1.9,"enterpriseToRevenue":2.67,"enterpriseToEbitda":12.1,"pegRatio":0.13,"ebitda":889624000,"ebitdaMargin":22.1,"freeCashflow":510023744,"operatingCashflow":607025984,"totalDebt":3064531968,"debtToEquity":102.6,"currentRatio":1.36,"returnOnAssets":4.3,"returnOnEquity":-5.9,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":15,"targetMeanPrice":209,"targetHighPrice":265,"targetLowPrice":135,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1,"institutionHeldPercent":115.2,"sharesOutstanding":48167730,"floatShares":47601759,"sharesShort":3349211,"shortRatio":4.11,"shortPercentOfFloat":7,"epsTrailing":-3.71,"epsForward":12.31,"revenuePerShare":81.96,"bookValue":64.3,"officers":[{"age":55,"name":"Ms. Birgit  Girshick","title":"CEO & Director"},{"age":48,"name":"Mr. Michael Gunnar Knell","title":"Corporate Senior VP & Chief Accounting Officer"},{"age":51,"name":"Mr. Joseph W. LaPlume J.D.","title":"Corporate Executive Vice President of Corporate Development & Strategy"},{"age":55,"name":"Ms. Victoria L. Creamer","title":"Corporate Executive VP & Chief People Officer"},{"age":57,"name":"Mr. Glenn G. Coleman CPA","title":"Corporate Executive VP & CFO"},{"age":null,"name":"Prof. Julie  Frearson Ph.D.","title":"Corporate Senior VP & Chief Scientific Officer"},{"age":51,"name":"Mr. Mark  Mintz","title":"Corporate EVP, Chief Information Officer & Global Shared Services"},{"age":null,"name":"Mr. Todd  Spencer","title":"Corporate Vice President of Investor Relations"}],"industry":"Diagnostics & Research","irWebsite":"http://ir.criver.com/phoenix.zhtml?c=121668&p=irol-irhome","website":"https://www.criver.com","phone":"781 222 6000"}}